GlassScriptPhysician profile
Karl A Guter
NPI 1437150331
$8,618.69
in general payments reported to CMS, 2019-2025
62 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,656 · 2020: $312 · 2021: $526 · 2022: $495 · 2023: $2,073 · 2024: $2,481 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,331 · Consulting Fee: $175 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,330.94 |
| Consulting Fee | $175.00 |
| Education | $123.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $991.01 | 2019-2025 | Opdivo, Opdualag, Sprycel |
| Merck Sharp & Dohme LLC | $667.36 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $645.79 | 2021-2025 | Rybrevant, Darzalex, Erleada |
| Astrazeneca Pharmaceuticals LP | $553.79 | 2019-2025 | Imfinzi, Lynparza, Calquence |
| Amgen INC. | $479.76 | 2019-2025 | Lumakras, Xgeva, Vectibix |
| Alexion Pharmaceuticals, INC. | $404.48 | 2021-2025 | Ultomiris |
| Pharmacyclics LLC, An Abbvie Company | $393.08 | 2019-2023 | Imbruvica |
| Novartis Pharmaceuticals Corporation | $365.87 | 2019-2024 | |
| Pfizer INC. | $341.24 | 2019-2025 | |
| Genzyme Corporation | $299.46 | 2019-2023 | |
| Beigene USA, INC. | $292.71 | 2023-2024 | Brukinsa, Tevimbra |
| Jazz Pharmaceuticals INC. | $270.76 | 2019-2025 | |
| Astellas Pharma US INC | $251.82 | 2019-2024 | Xtandi, Padcev |
| Blueprint Medicines Corporation | $224.81 | 2021-2024 | Ayvakit |
| Adaptive Biotechnologies Corporation | $155.12 | 2023-2024 | Clonoseq |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $148.93 | 2021-2025 | Trodelvy |
| Seagen INC. | $140.31 | 2019-2023 | Tukysa, Padcev |
| Emd Serono, INC. | $130.00 | 2024 | |
| Celgene Corporation | $113.65 | 2019-2021 | |
| Eisai INC. | $112.49 | 2019-2024 | |
| Incyte Corporation | $108.90 | 2019-2024 | Jakafi, Monjuvi |
| Genentech USA, INC. | $101.27 | 2019-2024 | Lunsumio, Polivy, Gazyva |
| US Oncology Corporate, INC. | $95.62 | 2023 | |
| Abbvie INC. | $94.87 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.31 | 2019-2024 | Ninlaro, Fruzaqla |
| Glaxosmithkline, LLC. | $84.41 | 2021-2025 | Ojjaara |
| Acrotech Biopharma INC. | $74.72 | 2023-2024 | Beleodaq |
| Lilly USA, LLC | $71.22 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Regeneron Healthcare Solutions, INC. | $66.66 | 2021-2024 | Libtayo |
| Sumitomo Pharma America, INC. | $65.81 | 2023-2024 | Orgovyx |
| Daiichi Sankyo INC. | $60.66 | 2019-2024 | Injectafer, Enhertu |
| Agios Pharmaceuticals, INC. | $60.30 | 2019-2024 | Pyrukynd |
| Genmab U.S., INC. | $55.54 | 2023-2025 | Tivdak |
| Ipsen Biopharmaceuticals, INC | $43.17 | 2019 | |
| Coherus Oncology, INC. | $41.99 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.57 | 2019-2023 | |
| Pharmaessentia USA Corporation | $36.70 | 2023-2024 | Besremi |
| Stemline Therapeutics INC. | $35.24 | 2023-2025 | Orserdu |
| Medtronic, INC. | $33.98 | 2024 | Illumisite |
| Aurobindo Pharma USA, INC. | $27.60 | 2019-2020 | |
| Pharming Healthcare, INC. | $23.82 | 2023 | Ruconest |
| Novocure INC. | $22.00 | 2019 | |
| Abbott Laboratories | $20.37 | 2024 | Freestyle Libre 3 |
| Exelixis INC. | $19.61 | 2024 | Cabometyx |
| Foundation Medicine, INC. | $18.94 | 2020 | |
| Servier Pharmaceuticals LLC | $18.47 | 2024 | |
| Sobi, INC | $18.46 | 2023 | |
| Janssen Pharmaceuticals, INC | $18.06 | 2024 | Xarelto |
| Exact Sciences Corporation | $17.63 | 2025 | The Cologuard Plus Collection Kit |
| Kite Pharma, INC. | $16.11 | 2023 | |
| Helsinn Therapeutics (U.S.), INC. | $15.83 | 2019 | |
| Alnylam Pharmaceuticals INC. | $14.99 | 2024 | Oxlumo |
| Beone Medicines USA, INC. | $14.70 | 2025 | Brukinsa |
| Kyowa Kirin, INC. | $14.47 | 2023 | Poteligeo |
| Karyopharm Therapeutics INC. | $13.66 | 2024 | Xpovio |
| Mirati Therapeutics, INC. | $13.53 | 2024 | Krazati |
| Aveo Pharmaceuticals, INC. | $13.36 | 2023 | Fotivda |
| Clovis Oncology, INC. | $13.31 | 2019 | |
| Puma Biotechnology, INC. | $12.77 | 2023 | |
| Myovant Sciences INC. | $12.32 | 2021 | |
| Morphosys, US INC. | $11.30 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karl Guter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.